ASENT 2022

ANNUAL MEETING

Opening Symposium:
February 28, 2022

Virtual Neuroscience and
Neurotherapeutics Conference

ADVANCE PROGRAM
Virtual MeetingFeb 28 - Mar 3, 2022
REGISTER TODAY: https://asent2022reg.eventbrite.com

ASENT 2022 Annual Meeting

About ASENT 2022
Annual Meeting Overview

WHAT IS ASENT?

ASENT 2022 is the premier neurotherapeutics conference where senior
executives from leading payers, providers, employers, academic
institutions, investors, fast-growing startups, pharma, policymakers,
advocate organizations, funders and innovation centers in the neurology
and neuroscience space gather to ask one question: how can we improve
the process of bringing neurotherapeutics to market?
The plenary sessions, panel discussions, networking meetings, outstanding
pipeline presentations and poster sessions will focus on the latest sciencein neurotherapeutics including innovations in rare disease, antisense
technology across disease states, novel delivery systems, gene therapy
and biomarkers, and of course the latest drug therapies and devices.

WHO ATTENDSASENT 2022 Meeting Dates
Monday, February 28 Thursday, March 3, 2022
VIRTUAL FORMATABSTRACT SUBMISSIONSOpen through December 13, 2022
https://www.eventbrite.com/e/
189784930837
REGISTRATION
Visit: https://
asent2022reg.eventbrite.com
Meeting Location
ONLINE

Physician-Scientists
Neurologists
Neuroscientists
Fellows
Postdocs
Trainees
Founders
Funders
Investors
Industry Leader

The American Society
for Experimental
Neurotherapeutics(ASENT) is anindependent non-profit
organization
established in 1997 byleaders in academia,
government, advocacy
and industry to facilitate
the process by which
new therapies are
made available topatients withneurological disorders.
Its primary goal is toencourage andadvance thedevelopment of novel
and improved therapies
for diseases anddisorders of thenervous system.

NonProfit Organizations(NORD, Alzheimer’s Assoc. etc.)

Journal Editors
Drug and Device Companies
Communication Companies
Representatives from NIH,
NIA, NIDA, NINDS and FDA

Page 2

ASENT 2022 SCHEDULE AT A GLANCEMONDAY, FEBRUARY 28, 2022

10:00 a.m. – 12:00 p.m.

Presidential Symposium
Rare Neurological Diseases– presented in partnershipwith National Organization for
Rare Disorders (NORD)

12:00 p.m. – 12:15 p.m.

Break

12:15 p.m – 1:30 p.m.

Concurrent Symposia
Antisense Oligonucleotide
Therapy in Rare Neurological
Diseases

TUESDAY, MARCH 1, 2022

10:00 a.m. – 11:15 p.m.

Plenary Session
Alzheimer’s Disease After
Aducanumab

11:15 a.m. – 11:30 a.m.

Break

11:30 a.m – 12:45 p.m.

Concurrent Symposia
Devices and Software as
Therapeutics for SubstanceUse Disorders (SUD)
Translational Bioinformatics
in Drug Repurposing andcombination therapy
development for Alzheimer's
DiseaseEmerging Brain Lipid
Pharmacology for
Neurodegenerative Disorder
1:30 p.m. – 2:30 p.m.

2:30 p.m. – 3:00 p.m.

Sponsored Symposium

11:15 a.m. – 11:30 a.m.
11:30 a.m – 12:45 p.m.

Break

1:00 p.m. – 3:00 p.m.

Pipeline Presentations
Emerging Neurotherapeutics
Presentations

Poster Discussion

WEDNESDAY, MARCH 2, 2022

10:00 a.m. – 11:15 p.m.

12:45 p.m. – 1:00 p.m.

Plenary Session
Emerging Science of the
Exposome and Its
Significance to
Neurotherapeutics
Break

THURSDAY, MARCH 3, 2022

10:00 a.m. – 11:30 p.m.

Plenary Session
Covid-19 and The Brain:
Update 2022

11:30 a.m. – 11:45 a.m.

Break

11:45 a.m – 1:00 p.m.

Concurrent Symposia
Not a One-Trick Pony:
Repurposing Established
Drugs for New Neurological
Indications
New Approaches to Pain
Therapeutics R&D: Models
and Results from Academic
and Industry Sectors

1:00 p.m. – 1:15 p.m.

Break

1:15 p.m. – 2:15 p.m.

Sponsored Symposium

2:15 p.m. – 2:45 p.m.

Poster Discussion

Concurrent Symposia
Innovative Treatments for
Rare Neurodevelopmental
Diseases
The Use of Digital Monitoring
Devices in Neurological
Clinical Studies

12:45 p.m. – 1:00 p.m.
1:00 p.m. – 3:00 p.m.

Page 3

Break
Pipeline Presentations
Emerging Neurotherapeutics
Presentations

ASENT 2022 Detailed Virtual Program
MONDAY, FEBRUARY 28, 2022
10:00 a.m. – 12:00 p.m.

Presidential Symposium
Rare Neurological Diseases – presented in partnership with National
Organization for Rare Disorders (NORD)
This symposium will include the global view of Rare Diseases therapeutic development through thelens of the National Organization for Rare Disorders including barriers and successes. Presentations
will feature examples such as ASO's and the Batten disease story, as well as drug development inDuchenne Dystrophy.
CHAIR: Bennett Lavenstein, MD, Children’s National Hospital
CO-CHAIR: Thomas Sutula, MD, PhD, University of Wisconsin, Madison
FACULTY
Peter Saltonstall, National Organization of Rare Disorders
Timothy Yu, MD, PhD, Boston Children’s Hospital
Edward Neilan, MD, PhD, National Organization of Rare Disorders
Edward Kaye, MD, Stoke Therapeutics

12:00 p.m. – 12:15 p.m.

BreakConcurrent Symposia
Antisense Oligonucleotide Therapy in Rare Neurological Diseases

12:15 p.m – 1:30 p.m.

We have demonstrated that gene modification of a previously untreatable disease, spinomuscularatrophy, is feasible. Here, we will explore how to apply these advances more broadly to rareneurological diseases. Developing meaningful interventions will require coordination across multiple
domains and stakeholders. The session will discuss recent advances in antisense oligonucleotide
therapy, including delivery, toxicity, manufacturing, clinical trial design and regulatory issues.
CHAIR: Bryan J. Traynor, MD, PhD, National Institutes of Health, National Institute on Aging
CO-CHAIR: C. Anthony Altar, PhD, Splice Therapeutics
FACULTY
Peter Hagedorn, MSc, PhD, Roche Pharma
Matthew Wood, MD, DPhil, University of Oxford
Jonathan Watts, University of Massachusetts Medical School

Emerging Brain Lipid Pharmacology for Neurodegenerative Disorder
Lipids account for up to 50% of the brain’s dry weight and comprise thousands of distinct biochemical
structures whose subcellular and intracellular expression regulates many levels of neurobiology
including organelle homeostasis, synaptic function, stress responses, cell death, in ammation andrepair. Not surprisingly, a key role for lipid biochemistry dysregulation has been emerging inneurological disorders involving myelin repair, neuroin ammation, and neurodegeneration. Indeed, themajor genetic risk factors driving Alzheimer’s disease and Parkinson’s disease, the most common
neurodegenerative disorders, participate in lipid homeostasis (APOE4 and GBA respectively).
Advances in genomic, proteomic and lipidomic technologies as well as translational model systems areproviding new opportunities for pharmacological approaches to regulate brain lipids. Several suchapproaches are currently in clinical development and are taking advantage of readily available
peripheral lipid biomarkers
CHAIR: Ajay Verma, MD, Yumanity
CO-CHAIR: Aditya Joshi, MD, University of Pennsylvania
FACULTY
Peter Lansbury, PhD, Bial Biotech
Jeroen Bogie, PhD, Hasselt University
Jason Ulrich, PhD, Washington University at St. Louis
Ajay Verma, MD, Yumanity
1:30 p.m. – 2:30 p.m.

Sponsored Symposia

2:30 p.m. – 3:30 p.m.

Poster Discussion

fl

fl

.

 

Page 4

ASENT 2022 Detailed Virtual Program
10:00 a.m. – 11:15 p.m.

TUESDAY, MARCH 1, 2022
Plenary Session

Alzheimer’s Disease After Aducanumab
The goal of the symposium is to present the economic and healthcare industry implications of thecontroversial regulatory approval of Aducanamab, a fair-minded review of the evidence, theprocess, an overview of the implications for future Alzheimer’s and other neurologic drug
development as well as other research areas in AD that are possible, such as Amyloid backups,
Tau, and inflammation.
CHAIR: Andrew J. Cole, MD, FRCP(C), Harvard Medical School

11:15 a.m. – 11:30 a.m.
11:30 a.m – 12:45 p.m.

FACULTY
Jalayne Arias, JD, MA, University of California, San Francisco
Karl Herrup, PhD, University of Pittsburgh School of Medicine

BreakConcurrent Symposia

Devices and Software as Therapeutics for Substance Use Disorders(SUD)

Exacerbated by COVID-19, the opioid epidemic continues to ravage the United States. In addition
to canonical pharmacologic and psychological approaches to SUD treatment, innovative devicebased therapeutic solutions, including software as medical device, have recently emerged. During
this symposium, the executives from some of the most disruptive and innovative device startups intoday’s healthcare ecosystem will discuss the opportunities and challenges of this new field.
CHAIR: Stacie Gutowski, PhD, National Institute of Health, National Institute of Drug Abuse
FACULTY
Athena Robinson, PhD, Woebot Health
Yuri Maricich, MD, MBA, Pear Therapeutics
Navid Khodaparast, PhD, Spark Biomedical

Translational Bioinformatics in Drug Repurposing and Combination
Therapy Development for Alzheimer's Disease

The emergence of biomedical big data and advances in computational technology have createdunprecedented opportunities for drug repositioning and combination therapy development,
particularly for CNS diseases including Alzheimer’s Disease (AD). In this symposium, you will havethe opportunity to hear the most recent progress made from academic investigators, and to learn
from biopharma senior scientists in sharing their drug repurposing effort from industry. The
opportunities and challenges will also be discussed to help realize the full potential of drug
repurposing for AD and CNS diseases.
CHAIR: Jean Yuan, PhD, National Institute of Health, National Institute on Aging

12:45 p.m. – 1:00 p.m.
1:00 p.m. – 3:00 p.m.

FACULTY
Pankaj Agarwal, PhD, BioInfi
Mark W. Albers, PhD, Massachusetts General Hospital, Harvard Medical School
Yadong Huang, MD, PhD, University of California, San Diego

Break

Pipeline Presentations

The ASENT Pipeline Sessions are brief podium presentations. These presentations are derived
from the abstract submissions and vetted by our abstract review committee to ensure the highest
caliber and most novel research.
CHAIR: Stewart Factor, DO, Emory University
CO-CHAIR: Carolyn Tallon, PhD, Johns Hopkins University

Page 5

ASENT 2022 Detailed Virtual Program
10:00 a.m. – 11:15 p.m.

WEDNESDAY, MARCH 2, 2022
Plenary Session
Emerging Science of the Exposome and Its Significance to
Neurotherapeutics

The exposome is defined as all exposures a person receives during the lifespan including internal(e.g., microbiome) and external (e.g., physical-chemical, social) sources. Major progress is being
made in data collection, curation, and analysis. This session will discuss the exposome concept,
significance of the exposome within the neurological disease community, and scientific approaches
to advance the field of exposome research and how these could be used in experimental
neurotherapeutics.
CHAIR: David Jett, PhD, National Institutes of Health

11:15 a.m. – 11:30 a.m.
11:30 a.m – 12:45 p.m.

FACULTY
Yuxia Cui, PhD, National Institute of Environmental Health Sciences
Eva L. Feldman, MD, PhD, University of Michigan

BreakConcurrent Symposia
Innovative Treatments for Rare Neurodevelopmental Diseases

Neurodevelopmental disease-modifying drug discovery is increasing enormously, however, highunmet needs remain. This is notably true for more rare monogenetic disorders, such as Angelman,
Rett, and Dravet syndromes, and across modalities (eg. small molecule, gene therapy and antisense
oligonucleotides). This symposium will discuss scientific advances, hurdles in drug development anddelivery, and a fair-balanced review of advantages and disadvantages from bench to bedside.
CHAIR: Joseph Sullivan, MD, University of California San Francisco
CO-CHAIR: Elizabeth Berry-Kravis, MD, PhD, Rush University Medical Center
FACULTY
Allyson Berent, DVM, DACVIM, GeneTx Biotherapeutics
Rob Komorowski, PhD, Ionis Pharmaceuticals
Kimberly A. Parkerson, MD, Stoke Therapeutics

The Use of Digital Monitoring Devices in Neurological Clinical Studies

In many neurodegenerative diseases, we see the measures of quality of life, mobility, quality of sleep
etc., as measurements that may reflect the stage of the disease. While QoL questionnaires rely on
subjective reporting of patients, digital monitoring devices can bridge this gap by allowing forquantitative, frequent, reliable and clinically meaningful measurements of the state of patients in their
daily lives. This rich dataset can help us monitor the treatment response and disease progression.
CHAIR: Sharon Tamir, Karyopharm Therapeutics
CO-CHAIR: Suhayl Dhib-Jalbut, MD, Rutgers Health

12:45 p.m. – 1:00 p.m.
1:00 p.m. – 3:00 p.m.

FACULTY
Jamie Lynn Adams, MD, University of Rochester Medical Center
Amir Lahav, ScD, Redenlab

Break
Pipeline Presentations
Emerging Neurotherapeutics Pipeline Presentations
CHAIR: Stewart Factor, DO, Emory University
CO-CHAIR: Carolyn Tallon, PhD, Johns Hopkins University

Page 6

ASENT 2022 Detailed Virtual Program
10:00 a.m. – 11:30 p.m.

THURSDAY, MARCH 3, 2022
Plenary Session
Covid-19 and The Brain: Update 2022

This plenary session features Dr. Avindra Nath, MD, PhD, of the NIH, who will address theneurological involvement and potential mechanism(s) of Covid-19 toxicity in the CNS. Our otherspeakers will describe brain imaging, function, and mechanism studies that reveal long-term CNS
consequences of Covid-19 infection in adults and children. Speakers will present up-to-date evidence
on how the virus creates CNS damage and compromises functions, as evidenced by sensory,
cognitive, and behavioral impairments that last beyond the typical symptoms of Covid-19.
CHAIR: C. Anthony Altar, PhD, Splice Therapeutics

11:30 p.m. – 11:45 p.m.
11:45 a.m – 1:00 p.m.

FACULTY
Avindra Nath, MD, PhD, National Institute of Health, National InstituteDr. Ming Lim, Evelina London Children’s Hospital
Clinton Wright, MD, MS, National Institutes of Health

Break
Concurrent Symposia
Not a One-Trick Pony: Repurposing Established Drugs for New
Neurological Indications
Many diseases have multifactorial pathophysiology, creating an opportunity to treat them withtherapies originally developed for different indications. Here, we will discuss the development of
products that utilize already established drugs from other elds of medicine for novel neurologicalindications
CHAIR: Sharon Tamir, Karyopharm Therapeutics
COCHAIR: Aditya Joshi, MD, University of Pennsylvania
FACULTY
Machelle Manuel, PhD, Amylyx
Shiran Zimri, PhD, Neurosense
Takashi Yamamura, MD, PhD, National Institute of Neuroscience in Tokyo

New Approaches to Pain Therapeutics R&D: Models and Resultsfrom Academic and Industry Sectors

Development of novel pain therapeutics continues to present significant challenges, demonstrated bydata showing only a 2% probability of drug approval for Phase I candidate pain therapeutics,
compared to an overall 10% probability in other disease areas. Challenges include unknown
neurobiological mechanisms of pain, translation of preclinical data, large placebo effects and disease
population heterogeneity. Recently, much more emphasis has been placed on the urgent need todevelop successful non-addictive therapeutics for pain as a result of efforts to address the opioid
crisis. This symposium will include an overview of new models for pain therapeutics that address thechallenge of pain therapeutics development from several perspectives including those representing
the scientific, process management and financial challenges.
CHAIR: Mary Ann Pelleymounter, PhD, National Institutes of Health/National Institute of Neurological
Disorders and Stroke
COCHAIR: Debra Ehrlich, MD, MS, National Institutes of Health/National Institute of Neurological
Disorders and Stroke
FACULTY
Michael Oshinsky, PhD, National Institutes of Health/National Institutes of Neurologic Disorders andStrokeKelly Knopp Palmer, Eli Lilly and Company
Haim Belinson, MSc, PhD, BSense BioTherapeutics

1:15 p.m. – 3:15 p.m.
3:15 p.m. – 3:45 p.m.

Feb 28 - Mar 3, 2022.

Page 7

Break
Sponsored Symposium
Poster Discussionfi

1:00 p.m. – 1:15 p.m.

7

#ASENT2022

ASENT 2022 Registration Options
Registration is now open for the ASENT 2022 Virtual Annual Meeting! Be sure to take amoment to register and join your colleagues for this exciting event!

REGISTRATION RATESReg Type

Reg Rate

Pharma, Biotech, Medtech

FREE

Academic Neurology/Neuroscience

FREE

Government Employee

FREE

Retired

FREE

Student/Trainee

FREE

NGO/Advocacy Organization/Family Foundation

FREE

Neurotherapeutics Course Alumni

FREE

NOTE: We hope to be back in person in 2023. The in person meeting registration rates will be reflective of
hotel, travel, food and beverage costs. Please bear this in mind as you budget for the coming year.

How to Register
Step 1: Visit: https://asent2022reg.eventbrite.com
Step 2: Look for confirmation email
Step 3: Follow directions in confirmation email to visit annual meeting platform
and complete your profile in advance of the meeting.
Step 4: Join the meeting on Feb 28 - Mar 3, 2022
(don’t worry we’ll remind you)
Bonus: Become a member so you have access to the recorded sessions all year
ASENT 2022 Session Recordings

All Virtual Annual Meeting registrations also include access to the ASENT 2022 Annual Meeting Sessions
Recordings for a period of 7 days. Active ASENT members will have unlimited access to the recordings beyond
the initial 7 day period.
ASENT Members will have the ability to watch key sessions on-demand throughout the year. They will be able
to take advantage of key sessions they may have missed. Note: Specific sessions and some presentations
within a session may not be available if the presenter has not granted permission to repurpose theirpresentation.
To learn more about ASENT membership, scroll down or contact the ASENT team at caroline@asent.org.

Feb 28 - Mar 3, 2022

8

#ASENT2022
Page 8ASENT 2022 Leadership
PROGRAM COMMITTEE

BOARD OF DIRECTORSCHAIRSEXECUTIVE COMMITTEEC Anthony Altar, PhD, Chair
Splice Therapeutics
Sharon Tamir, Co-Chair
Karyopharm Therapeutics

Thomas Sutula, MD, PhD, PRESIDENT
University of Wisconsin
Andrew J. Cole, MD, FRCP(C), VICE PRESIDENT
Massachusetts General Hospital/Harvard Medical School
Martha Morrell, MD, PAST PRESIDENT
NeuroPace

COMMITTEE MEMBERS
Enrique Carrazana, MD
Neurelis, Inc.
Amy Chappell, MD
Eliam
Suhayl Dhib-Jalbut, MD
Rutgers-Robert Wood Johnson Medical School
Tracy Dixon-Salazar, PhD
Lennox Gastaut Foundation
Debra Ehrlich, MD, MS
NINDS
Stewart Factor, DO
Emory University
Gail Farfel, PhD
Zogenix
Wendy Galpern, MD, PhD
Johnson and Johnson
Dietrich Haubenberger, MHSc, MD
Neurocrine
Aditya Joshi, MD
University of Pennsylvania
Laura Rosen, MD, PhD
TakedaCynthia Rothblum-Oviatt, PhD
RO ScientificNancy Santilli, MSN
Human Care Systems
Steve Schachter, MD
CIMIT/Harvard Medical School
Carolyn Tallon, PhD
Johns Hopkins University
Danilo Vitorovic, MD
University of Vermont
Amir Tamiz, PhD

BOARD MEMBERS
Enrique Carrazana, MD
Neurelis, Inc.
Amy Chappell, MD
Eliam
Stewart A. Factor, DO
Emory University School of Medicine
Gail Farfel, PhD
Zogenix
Toby Ferguson, MD, PhD
Biogen Idec, Inc
Dietrich Haubenberger, MHSc, MD
Neurocrine
Aditya Joshi, MD
University of Pennsylvania
Bennett L, Lavenstein, MD
Children’s Hospital Medical Center
Steven Schachter, MD
CIMIT/Harvard Medical School
C Anthony Altar, PhD
Splice Therapeutics
Sharon Tamir
Karyopharm Therapeutics
Danilo Vitorovic, MD
University of Vermont

Become an
ASENT Member
Join a community of professionals inindustry, government, academia andadvocacy working together to bringneurotherapeutics to market.
Visit: https://members.asent.org/Membership
Page 9

Register Today:
https://asent2022reg.eventbrite.com

Feb 22-25, 2021

#ASENT2021

Page 10